You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
NEW YORK – Elios Therapeutics reported 24-month survival data from a trial investigating its tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine in patients with advanced, resected melanoma.
...and receive Weekly News bulletins.
Already have a Precision Oncology News or 360Dx or GenomeWeb account?Login Now.
Don't have a Precision Oncology News or 360Dx or GenomeWeb account?Register for Free.